Compare Sanofi SA (SNY) vs Xcel Energy Inc (XEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Xcel Energy Inc — how do they compare? Sanofi SA trades at $42.7 (market cap $104.06B), while Xcel Energy Inc trades at $76.24 (market cap $48.02B). The key difference: Sanofi SA is far larger — about 2.2× Xcel Energy Inc's market cap, and Sanofi SA pays the higher dividend (5.61%). Which is the better fit depends on your goals.
| SNY | XEL | |
|---|---|---|
Market Cap | $104.06B | $48.02B |
Sector | Health | Utilities |
52-Week High | $52.34 | $83.91 |
52-Week Low | $41.33 | $72.05 |
Enterprise Value | $124.09B | $86.33B |
Dividend Yield | 5.61% | 3.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sanofi (SNY) trades at $43.155, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported strong Q2 2026 earnings, beating expectations with EPS of $1.21 versus $1.10 expected, and raised full-year guidance. Recent FDA approvals for COVID vaccines and EU approval for MenQuadfi in infants provide positive catalysts, though pipeline setbacks with an eczema drug withdrawal create uncertainty.
SNY presents a mixed outlook with solid fundamentals including a 5.4% dividend yield and reasonable valuation (P/E 22.94), but faces execution risks under new CEO leadership. Analyst consensus leans Hold (51.86%) with price target of $49.50, suggesting moderate upside potential. Key risks include drug pipeline challenges and competitive pressures in the pharmaceutical sector.
XEL trades at $76.88, up 1.53% on the day, with a bearish technical signal but strong analyst consensus. Recent Q2 2026 earnings beat estimates at $0.93 per share. The company maintains solid profitability with a 15.28% net income margin and is executing a $70B+ capital investment plan through 2030 to drive growth. Dividend payments remain consistent at $0.59 quarterly.
Outlook is positive with a $92 consensus price target, though risks include high capital expenditures, regulatory scrutiny from wildfire lawsuits, and rising interest rates. The stock offers stable income and growth potential but faces execution and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Xcel Energy Inc
Xcel Energy manages utilities serving 3.7 million electric customers and 2.1 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan
Read more on XEL →
